Zambon has completed the patient enrolment of patients in its two pivotal Phase III trials of Liposomal Cyclosporine A for Inhalation (L-CsA-i) to treat bronchiolitis obliterans syndrome (BOS).

Designed to assess the safety and efficacy of L-CsA-i, the trials have enrolled adults with BOS following single lung (BOSTON-1) or double lung (BOSTON-2) transplantation.

A total of 231 patients from Europe, Israel and the US were enrolled for both the studies and 42 lung transplant centres have participated altogether.

Zambon chief medical officer and R&D head Paola Castellani said: “The completion of enrolment in our Phase III BOSTON-1 and BOSTON-2 studies represents a significant milestone for Zambon and the patient community we aim to serve.

“On behalf of the company, we would like to thank the many participants in our Phase III clinical programme, as well as our study sites and investigators for their commitment. We look forward to reporting top-line results from the programme during 2024.”

The company also plans to initiate an extension study, BOSTON-3, and enrol eligible patients who complete both trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An inhaled therapy, L-CsA-i is administered using the optimised investigational eFlow Technology nebuliser system, developed by PARI Pharma.

A rapidly progressive inflammatory rare disease, BOS irreversibly destroys the lungs’ airways leading to respiratory failure and death within two to four years following diagnosis.